Rotation Medical Appoints Michael J. McNulty Vice President of Sales and Marketing
Plymouth, MN –May 1, 2014 –Rotation Medical, a medical device company focused on developing new technologies to treat rotator cuff disease, today announced that Michael J. McNulty has joined the company as Vice President of Sales and Marketing. McNulty will lead Rotation Medical’s commercialization and sales efforts as the company prepares for the market introduction of its arthroscopic rotator cuff implant system.
“Michael has a demonstrated ability to introduce new products and concepts to the market and drive clinical adoption,” said Martha Shadan, Chief Executive Officer and President of Rotation Medical. “I believe that his strong sales track record, combined with his clinical selling capabilities and strong training and team development skills make him ideally suited to lead Rotation Medical’s sales and marketing efforts throughout our next stage of growth and development.”
McNulty brings to Rotation Medical more than 16 years of global medical device commercial experience at both large and small companies. Most recently he served as Vice President of Sales for Arstasis where he was responsible for market development, commercial launch, sales training and sales management. Under McNulty’s leadership, Arstasis achieved consistent sales growth and introduced a novel arterial access procedure to the diagnostic/interventional cardiology, interventional radiology, vascular surgery and neurology markets. Previously McNulty served in multiple roles at Cordis, a Johnson & Johnson Company, where he helped launch several disruptive technologies to the market and led sales training and sales management for both the Cardiology and Endovascular divisions. McNulty served as an officer in the Armor Cavalry Branch of the United States Army from 1995-1998. He holds a Bachelor of Arts degree and graduated with honors from Clemson University.
“I believe that the Rotation Medical Bioinductive Implant technology has tremendous potential to significantly improve how rotator cuff disease is managed today, and I look forward to working with my colleagues to realize the fullest potential for this innovative technology,” said McNulty.
About Rotation Medical
Rotator cuff tears are the most common source of shoulder pain and diminished shoulder function in adults. Rotator cuff disease is a progressive condition with prevalence increasing with age. Rotation Medical was founded in 2009 and is committed to improving the treatment of rotator cuff disease with the Rotation Medical Rotator Cuff System™, a breakthrough technology that has the potential to prevent rotator cuff disease progression and reduce re-tears by inducing the growth of new tendinous tissue. The Rotation Medical Rotator Cuff System combines a unique, proprietary bioinductive implant designed to rapidly induce tendinous tissue growth with a set of novel, arthroscopic disposable instruments that allow the procedure to be performed quickly and reproducibly. For more information visit www.rotationmedical.com.
Rotation Medical received 510(k) clearance from the Food and Drug Administration (FDA) for its implantable bioinductive implant technology in March 2014. A mid-2014 launch is planned in the U.S.